araag2/HINT huggingface dataset:
Clinical trial NCT03110380 (phase 3, status: active, not recruiting)
Conditions: hiv-1-infection
ICD codes: B20, Z71.7, O98.72, Z21, O98.73, R75, Z11.4
Drugs: b/f/taf, f/taf, dtg, dtg placebo, f/taf placebo, b/f/taf placebo
SMILES: CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O, CC(C)OC(=O)[C@H](C)N[P@](=O)(CO[C@H](C)CN1C=NC2=C(N)N=CN=C12)OC1=CC=CC=C1, [H][C@]12CN3C=C(C(=O)NCC4=CC=C(F)C=C4F)C(=O)C(O)=C3C(=O)N1[C@H](C)CCO2, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
Eligibility criteria:

        Key Inclusion Criteria:

          -  Currently receiving an ARV regimen of DTG+F/TAF or DTG+F/TDF for the following minimum
             time periods:

               -  ≥ 6 months (if there is documented or suspected nucleoside/nucleotide reverse
                  transcriptase inhibitor (NRTI) resistance prior to the screening visit)

               -  ≥ 3 months (if there is no documented or suspected NRTI resistance prior to the
                  screening visit)

          -  Documented plasma HIV-1 RNA < 50 copies/mL during treatment with DTG+F/TAF or
             DTG+F/TDF (for a minimum period of ≥ 6 or ≥ 3 months, as applicable) preceding the
             screening visit

          -  Plasma HIV-1 RNA levels < 50 copies/mL at screening visit

          -  Estimated Glomerular Filtration Rate (eGFR) ≥ 30 mL/min according to the
             Cockcroft-Gault formula for creatinine clearance

          -  No documented resistance to integrase stand transfer inhibitors (INSTIs) or confirmed
             virologic failure

          -  Eligible adults with chronic hepatitis B virus (HBV) and/or hepatitis C virus (HCV)
             infection are permitted to enroll

        NOTE: Other protocol defined Inclusion/ Exclusion criteria may apply.
Clinical trial NCT03115112 (phase 3, status: completed)
Conditions: type 2 diabetes mellitus
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: bexagliflozin, sitagliptin, placebo for sitagliptin, placebo for bexagliflozin
SMILES: OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)C1=CC=C(Cl)C(CC2=CC=C(OCCOC3CC3)C=C2)=C1, N[C@@H](CC(=O)N1CCN2C(C1)=NN=C2C(F)(F)F)CC1=CC(F)=C(F)C=C1F, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of T2DM

          -  Currently taking metformin or taking metformin and one additional oral medication for
             diabetes

          -  Body Mass Index (BMI) ≤ 45 kg/m2

          -  Stable dose of blood pressure or cholesterol medications (if applicable) for at least
             30 days

        Exclusion Criteria:

          -  Hypersensitivity or other contraindication to the safe use of DPP-4 inhibitor or
             sitagliptin

          -  Diagnosis of type 1 diabetes mellitus or maturity-onset/diabetes of the young

          -  History of genitourinary tract infections

          -  Evidence of abnormal liver function

          -  History of pancreatitis

          -  Myocardial infarction, stroke or hospitalization for heart failure within 3 months of
             screening

          -  Evidence of kidney problems

          -  Pregnant or nursing
Clinical trial NCT03162055 (phase 3, status: completed)
Conditions: chronic obstructive pulmonary disease copd
ICD codes: G91.1, I42.1, N11.1, J05.0, G47.33, J44.9, N13.8
Drugs: glycopyrronium/formoterol fumarate, umeclidinium/vilanterol
SMILES: OCC1=C(O)C=CC(=C1)[C@@H](O)CNCCCCCCOCCOCC1=C(Cl)C=CC=C1Cl
Eligibility criteria:

        Inclusion criteria:

          -  Age 40-95 years at screening

          -  Current or former smoker with a history of at least 10 pack-years of cigarette smoking

          -  Current clinical diagnosis of COPD, with COPD symptoms > 1 year prior to screening, as
             defined by GOLD criteria or other current guidelines

          -  COPD Severity defined by FEV1/FVC ratio <0.70 and FEV1 <80% of predicted normal value
             at screening and at randomisation

          -  COPD treatment with rescue medication only, or stable dose of maintenance monotherapy
             (LAMA, LABA or ICS), or stable dose of double maintenance therapy (LAMA/LABA or
             ICS/LABA), for one month prior to screening

          -  COPD Assessment Test (CAT) score ≥10 at randomisation

          -  Documentation of a chest x-ray (as per local practice) or computed tomography (CT)
             within 6 months prior to screening, with no clinically significant pulmonary
             abnormalities other than related to COPD

        Exclusion criteria:

          -  Respiratory disease other than COPD, including:

          -  Current diagnosis of asthma

          -  Alpha-1 Antitrypsin Deficiency as the cause of COPD

          -  Other respiratory disorders and conditions as listed in the protocol

          -  Severe COPD exacerbation (resulting in hospitalisation) not resolved within 8 weeks
             prior to screening, or moderate exacerbation not resolved within 4 weeks, or during
             screening

          -  Pneumonia or lower respiratory tract infection that required antibiotics within 8
             weeks prior to screening, or during screening.

          -  Significant diseases or conditions other than COPD which may put the patient at risk,
             or influence the results of the study or the patient's ability to participate,
             including cardiac disease, advanced renal disease, and cancer that has not been in
             complete remission for at least 5 years.

          -  Patients who have needed additions or alterations to their usual maintenance therapy
             for COPD due to worsening symptoms within 1 month prior to and during screening

          -  Treatment with depot corticosteroids within 6 weeks, or other systemic corticosteroids
             within 4 weeks, prior to screening. (Patients maintained on an equivalent of 5 mg
             prednisone per day for at least 3 months prior to screening are allowed.)
Clinical trial NCT03184415 (phase 3, status: terminated)
Conditions: gastritis
ICD codes: K29.00, K29.01, K29.20, K29.21, K29.60, K29.61, K29.70
Drugs: dwc20155, dwc20156, placebo of dwc20155, placebo of dwc20156
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    lack of efficacy
  
Eligibility criteria:

        Inclusion Criteria:

          -  Male of female of at least 19 years old

          -  Patients diagnosed with acute or chronic gastritis by gastroscopy

          -  Patients with one or more erosions found by gastroscopy

        Exclusion Criteria:

          -  Patients with peptic ulcer and gastroesophageal reflux disease

          -  Patients with previous gastrointestinal surgery

          -  Patients with history of gastrointestinal cancer
Clinical trial NCT03186365 (phase 3, status: completed)
Conditions: hepatitis c, chronic
ICD codes: B18.2, B18.0, B18.1, B18.8, B18.9, K71.3, K71.4
Drugs: zepatier oral product
SMILES: COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C1=NC(=CN1)C1=CC2=C(C=C1)N1[C@@H](OC3=C(C=CC(=C3)C3=CNC(=N3)[C@@H]3CCCN3C(=O)[C@@H](NC(=O)OC)C(C)C)C1=C2)C1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Treatment naïve, HCV genotype 1b patients

          -  History of chronic HCV infection > 6 months

          -  Aged at least 20 years

          -  HCV RNA of 10,000 IU/mL or greater

          -  Fibroscan examination < 9.5 Kpa

          -  Negative serum or urine pregnancy test result (sensitivity of 25 mIU or better) for
             women with childbearing potential within the 24-hour period before the first dose of
             study drugs

          -  Female patients with childbearing potential must agree to use two reliable forms of
             effective non-hormonal contraception (i.e., condoms, cervical barriers, intrauterine
             device, spermicides, or sponge), at least 1 of which must be a physical barrier
             method, during treatment till end of follow up.

          -  A hormonal contraception (in lieu of non-hormonal) plus a physical barrier method can
             be used after end of treatment. All men with female partners of childbearing potential
             must use two reliable forms of effective contraception (combined) during treatment and
             till end of follow up

          -  Ability to participate and willingness to give written informed consent and to comply
             with the study restrictions.

        Exclusion Criteria:

          -  Prior experience of IFN or direct antiviral agents (DAA)

          -  Hepatitis B virus or HIV co-infection.

          -  Patients with experience of ascites, esophageal varices, or other evidence of hepatic
             decompensation, and/or hepatocellular carcinoma.

          -  History of organ transplantation, except cornea transplantation.

          -  Hemoglobulin concentration < 11 mg/dl

          -  Platelet count < 75,000/mm3

          -  Albumin < 3 mg/dL

          -  History of active malignancy within the last 5 years, with the exception of localized
             or in situ carcinoma (e.g., basal or squamous cell carcinoma of the skin)

          -  Poorly controlled diabetes (Hemoglobin A1c value ≥ 8.5%) and endocrine condition.

          -  Total bilirubin >2 mg/dL, unless subject has a documented history of Gilbert's
             disease.

          -  Pregnant or lactating women.
Clinical trial NCT03191396 (phase 3, status: completed)
Conditions: diabetes, diabetes mellitus, type 2
ICD codes: E23.2, N25.1, P70.2, O24.92, Z83.3, Z86.32, E10.65, E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: semaglutide, liraglutide
SMILES: CC[C@H](C)[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CC[C@@H](NC(=O)CCCCCCCCCCCCCCCCC(O)=O)C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)C(C)(C)NC(=O)[C@@H](N)CC1=CNC=N1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O, CN(C)C(=N)NC(N)=N
Eligibility criteria:

        Inclusion Criteria: - Male or female, age 18 years or older at the time of signing informed
        consent - Diagnosed with type 2 diabetes mellitus - HbA1c of 7.0-11.0 % (53 - 97 mmol/mol)
        (both inclusive) - Stable daily dose(s) including any of the following anti-diabetic
        drug(s) or combination regimens 90 days prior to the day of screening: a) Biguanides
        (metformin above or equal to 1500 mg or maximum tolerated dose documented in the subject's
        medical record). b) Sulphonylureas (above or equal to half of the maximum approved dose
        according to local label or maximum tolerated dose as documented in subject medical
        record). c) SGLT-2 inhibitors (above or equal to half of the maximum approved dose
        according to local label or maximum tolerated dose as documented in subject medical record)
        Exclusion Criteria: - Family or personal history of multiple endocrine neoplasia type 2 or
        medullary thyroid carcinoma. Family is defined as a first degree relative - History or
        presence of pancreatitis (acute or chronic) - History of diabetic ketoacidosis - Any of the
        following: myocardial infarction, stroke, hospitalization for unstable angina or transient
        ischaemic attack within the past 180 days prior to the day of screening - Subjects
        presently classified as being in New York Heart Association (NYHA) Class IV - Planned
        coronary, carotid or peripheral artery revascularisation known on the day of screening -
        Renal impairment measured as estimated Glomerular Filtration Rate (eGFR) value of below 30
        ml/min/1.73 sqm as defined by KDIGO 2012 classification - Impaired liver function, defined
        as ALT above or equal to 2.5 times upper normal limit at screening - Proliferative
        retinopathy or maculopathy requiring acute treatment. Verified by fundus photography or
        dilated fundoscopy performed within the past 90 days prior to randomisation
Clinical trial NCT03214367 (phase 3, status: completed)
Conditions: type 1 diabetes mellitus
ICD codes: E10.65, E10.9, E10.21, E10.36, E10.41, E10.42, E10.44
Drugs: ly900014, insulin lispro, insulin glargine, insulin degludec
SMILES: [Na+].[Na+].[O-]P([O-])(F)=O, [Na+].[Na+].[O-]P([O-])(F)=O, [Na+].[Na+].[O-]P([O-])(F)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Have T1D for at least 1 year prior to screening and continuously using insulin for at
             least 1 year.

          -  HbA1c of ≥7.0 and ≤9.5%.

          -  Use insulin lispro, insulin aspart, or insulin glulisine as prandial insulin.

          -  Use insulin glargine, insulin detemir, insulin degludec, or neutral protamine Hagedorn
             (NPH) insulin as basal insulin.

        Exclusion Criteria:

          -  Have used other antihyperglycemic medications or therapies (inhaled, oral or
             injectable) within 90-days of screening.

          -  Have had more than 1 severe hypoglycemic episode within 6 months of screening.

          -  Have had more than 1 hospitalization related to hyperglycemia or diabetic ketoacidosis
             within 6 months of screening.

          -  Have clinically significant gastrointestinal disease.
Clinical trial NCT03214380 (phase 3, status: completed)
Conditions: type 2 diabetes mellitus
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: ly900014, insulin lispro, insulin glargine, insulin degludec, metformin, sglt2 inhibitor
SMILES: [Na+].[Na+].[O-]P([O-])(F)=O, [Na+].[Na+].[O-]P([O-])(F)=O, [Na+].[Na+].[O-]P([O-])(F)=O, CSCC[C@H](N)C(O)=O, [H][C@]1(O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)C1=CC=C(C)C(CC2=CC=C(S2)C2=CC=C(F)C=C2)=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Have been diagnosed (clinically) with T2D, based on the World Health Organization
             (WHO) classification for at least 1 year prior to screening.

          -  Have been treated for at least 90 days prior to screening with:

               -  Basal insulin (insulin glargine U-100 [Basaglar/Abasaglar or LANTUS] or U-300,
                  insulin detemir, insulin degludec U-100 or U-200, or neutral protamine Hagedorn
                  [NPH] insulin) in combination with at least 1 prandial injection of bolus insulin
                  (insulin lispro U-100 or U-200, insulin aspart, insulin glulisine, or regular
                  insulin) Or

               -  Premixed analog or human insulin regimens with any basal and bolus insulin
                  combination injected at least twice daily

          -  Participants may be treated with up to 3 of the following oral antihyperglycemic
             medications (OAMs) in accordance with local regulations:

               -  Metformin

               -  Dipeptidyl peptidase-4 (DPP-4) inhibitor

               -  Sodium glucose cotransporter 2 (SGLT2) inhibitor

               -  Sulfonylurea

               -  Meglitinide

               -  Alpha-glucoside inhibitor

          -  Have an HbA1c value between ≥7.0 and ≤10.0%, according to the central laboratory at
             the time of screening.

          -  Have a body mass index (BMI) of ≤45.0 kilograms per meter squared at screening.

        Exclusion Criteria:

          -  Have been diagnosed, at any time, with type 1 diabetes (T1D) or Latent Autoimmune
             Diabetes in Adults.

          -  Have hypoglycemia unawareness as judged by the investigator.

          -  Have had any episode of severe hypoglycemia within the 6 months prior to screening.

          -  Have had 1 or more episodes of diabetic ketoacidosis or hyperglycemic hyperosmolar
             state within the 6 months prior to screening.

          -  Have used thiazolidinediones, Glucagon-Like Peptide 1 (GLP-1) receptor agonist, or
             pramlintide within 90 days prior to screening.
Clinical trial NCT03225248 (phase 3, status: completed)
Conditions: functional dyspepsia
ICD codes: K30
Drugs: ui05msp015ct, gasmotin
SMILES: CCOC1=CC(N)=C(Cl)C=C1C(=O)NCC1CN(CC2=CC=C(F)C=C2)CCO1
Eligibility criteria:

        Inclusion Criteria:

          1. Age >19 years

          2. Diagnosis of functional dyspepsia meeting Rome III criteria

          3. At least three moderate or severe symptoms included in the Symptom Score

          4. No structural lesions of upper gastrointestinal tract

        Exclusion Criteria:

          1. History of dyspepsia unrelated to functional dyspepsia or diseases

          2. History of gastrointestinal surgery

          3. History of malignancy in the previous 5 years

          4. Psychiatric disorders including major depressive disorder and anxiety

          5. Liver cirrhosis or abnormal liver laboratory findings

          6. Advanced chronic kidney disease

          7. Uncontrolled hypertension

          8. Uncontrolled diabetes

          9. Pregnancy and lactation

         10. Recent history of taking medication affecting the gastrointestinal system
Clinical trial NCT03241472 (phase 3, status: completed)
Conditions: infertility
ICD codes: N46.8, N46.9, N97.9, N97.0, N97.1, N97.2, N97.8
Drugs: letrozole, clomiphene citrate plus n acetyl cystine
SMILES: N#CC1=CC=C(C=C1)C(N1C=NC=N1)C1=CC=C(C=C1)C#N, [H][C@@]12CC[C@](OC(C)=O)(C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])C[C@H](C)C2=CC(=O)CC[C@]12C
Eligibility criteria:

        Inclusion Criteria:

          -  All primary and secondary. Infertility due to anovulation

        Exclusion Criteria:

          -  Male factor infertility, tubal factor.

          -  Endocrineopathy

          -  Hypothyrodism

          -  Morbid obesity

          -  Under weight

          -  Patient with previous surgery including drilling of ovary, Clomiphene Citrate
             resistant to ovulation.
Clinical trial NCT03242018 (phase 3, status: completed)
Conditions: type 2 diabetes mellitus, chronic kidney disease stage 4
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: placebo, sotagliflozin (sar439954)
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CCOC1=CC=C(CC2=CC(=CC=C2Cl)[C@@H]2O[C@H](SC)[C@@H](O)[C@H](O)[C@H]2O)C=C1
Eligibility criteria:

        Inclusion criteria :

          -  Patients with Type 2 Diabetes (drug-naïve or on antidiabetic therapy) and documented
             severe renal insufficiency - CKD4 - defined by an estimated glomerular filtration rate
             (eGFR) equation (based on the 4 variable modification of diet in renal disease (MDRD)
             equation) of ≥15 and <30 mL/min/1.73 m2.

          -  Signed written informed consent to participate in the study in accordance with local
             regulations.

        Exclusion criteria:

          -  At the time of screening, age <18 years.

          -  Hemoglobin A1c (HbA1c) <7% or >11%.

          -  Type 1 diabetes.

          -  Women of childbearing potential (WOCBP) not willing to use highly effective method(s)
             of birth control during the study treatment period and the follow-up period, or who
             are unwilling or unable to be tested for pregnancy during the study.

          -  Treatment with an SGLT2 inhibitor (canagliflozin, dapagliflozin, empagliflozin) during
             the last 12 months.

          -  Uncontrolled high blood pressure, severe anemia, severe cardiovascular problems, such
             as heart failure, active cancer, or other conditions that the Investigator believes
             with result in a short life expectancy, will preclude their safe participation in this
             study, or will make implementation of the protocol or interpretation of the study
             results difficult.

          -  Lower extremity complications (such as skin ulcers, infection, osteomyelitis and
             gangrene) identified during the Screening period, and still requiring treatment at
             Randomization.

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
Clinical trial NCT03249181 (phase 3, status: active, not recruiting)
Conditions: hiv-1-infection, pregnancy related
ICD codes: B20, Z71.7, O98.72, Z21, O98.73, R75, Z11.4
Drugs: dolutegravir, standard of care (efv + 2 nrti backbone)
SMILES: N[C@@H](CO)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          1. Evidence of a personally signed and dated informed consent document indicating that
             the participant has been informed of all pertinent aspects of the study.

          2. Willing and able to comply with scheduled visits, treatment plan, laboratory tests,
             and other study procedures.

          3. Women aged 18 years or older

          4. Pregnant ( ≥28 weeks gestation by best available gestation estimation)

          5. Untreated HIV infection in late pregnancy

        Exclusion Criteria:

          1. Received any antiretroviral drugs in previous 12 months

          2. Ever received integrase inhibitors

          3. Previous documented failure of an NNRTI-containing ART regimen, previous
             EFV-associated toxicity or other history of ARV use that would preclude randomisation
             based on investigator judgement

          4. Serum haemoglobin <8.0 g/dl

          5. eGFR<50 ml/min*

          6. Elevations in serum levels of alanine aminotransferase (ALT) >5 times the upper limit
             of normal (ULN) or ALT >3xULN and bilirubin >2xULN (with >35% direct bilirubin).

          7. History or clinical suspicion of unstable liver disease (as defined by the presence of
             ascites, encephalopathy, coagulopathy, hyperbilirubinaemia, oesophageal or gastric
             varices or persistent jaundice).

          8. Severe pre-eclampsia (e.g. HELLP), or other pregnancy related events such as renal or
             liver abnormalities (e.g. grade 2 or above proteinuria,, total bilirubin, ALT or AST)*
             at the time of enrolment

          9. Paternal objection for infant participation in DTG arm (where disclosure has taken -
             applies to Uganda site only

         10. Medical, psychiatric or obstetric condition that might affect participation in the
             study based on investigator judgement

         11. Receiving any of the following medications (current or within past 2 weeks):
             anti-epileptic drugs, TB therapy, or other drugs known to significantly interact with
             either DTG or EFV
Clinical trial NCT03249376 (phase 3, status: completed)
Conditions: bipolar depression
ICD codes: F32.A, F53.0, P91.4, Z13.31, Z13.32
Drugs: lumateperone
SMILES: [H][C@]12CCN(CCCC(=O)C3=CC=C(F)C=C3)C[C@@]1([H])C1=CC=CC3=C1N2CCN3C
Eligibility criteria:

        Major Inclusion Criteria:

          -  male or female subjects of any race, ages 18-75 inclusive, with a clinical diagnosis
             of Bipolar I or Bipolar II disorder

          -  experiencing a current major depressive episode

          -  able to provide written informed consent

        Major Exclusion Criteria:

          -  any female subject who is pregnant or breast-feeding

          -  any subject judged to be medically inappropriate for study participation